PracticeVideosBlogFlashcardsEspañol

Free exam prep

ANCC-AGPCNP-BC

Practice QuestionsStudy Guide

7.2 Thyroid Disorders: Hypothyroidism, Hyperthyroidism, Thyroiditis & Nodules

Key Takeaways

  • Primary hypothyroidism is characterized by an elevated serum TSH and low Free T4; Hashimoto's (autoimmune) thyroiditis is the leading etiology in iodine-sufficient regions, confirmed by elevated anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin (anti-Tg) antibodies.
  • Levothyroxine (L-thyroxine) is dosed at ~1.6 mcg/kg/day ideal body weight in young, healthy adults, but older adults and patients with known coronary artery disease must start low ('start low and go slow': 12.5–25 mcg/day) to prevent precipitating angina, myocardial ischemia, or tachyarrhythmias.
  • Hyperthyroidism etiology is differentiated by 24-hour Radioactive Iodine Uptake (RAIU): diffuse, homogenous high uptake indicates Graves' disease; patchy, heterogeneous uptake indicates Toxic Multinodular Goiter; suppressed/low uptake (<5%) indicates subacute thyroiditis, postpartum thyroiditis, or factitious/exogenous thyrotoxicosis.
  • Subacute granulomatous (De Quervain's) thyroiditis is a post-viral inflammatory disorder presenting with an exquisitely painful, tender thyroid gland, markedly elevated ESR/CRP, low RAIU, and a triphasic clinical course (hyperthyroid → hypothyroid → euthyroid), treated with NSAIDs or oral prednisone.
  • Thyroid nodule evaluation begins with serum TSH: a suppressed TSH prompts a radionuclide iodine scan (hot nodules are rarely malignant); a normal or elevated TSH warrants neck ultrasound and risk stratification using ACR TI-RADS criteria to determine fine-needle aspiration (FNA) biopsy thresholds.
Last updated: August 2026

Thyroid Disorders: Hypothyroidism, Hyperthyroidism, Thyroiditis & Nodules

Thyroid disorders represent some of the most prevalent endocrine pathologies encountered in adult-gerontology primary care practice. Thyroid hormones (thyroxine [$T_4$] and triiodothyronine [$T_3$]) act on virtually every cell in the human body to regulate basal metabolic rate, cardiac inotropy/chronotropy, protein synthesis, lipid turnover, and neuromuscular excitability. Derangements in thyroid homeostatic circuitry manifest as subtle, insidious clinical syndromes in older adults or fulminant, life-threatening metabolic crises (myxedema coma and thyroid storm).

For the AGPCNP, board certification requires mastery of the hypothalamic-pituitary-thyroid (HPT) axis feedback loop, pharmacological nuances of replacement and suppression therapies, radioactive iodine uptake scan interpretation, thyroiditis differentiation, and evidence-based workups for thyroid nodules and malignancies.

1. The Hypothalamic-Pituitary-Thyroid (HPT) Axis & Diagnostic Serology

+---------------------------------------------------------------------------------------------------+
|                         HYPOTHALAMIC-PITUITARY-THYROID (HPT) AXIS                                 |
|                                                                                                   |
|                                  [HYPOTHALAMUS]                                                   |
|                                        |                                                          |
|                                        v (TRH: Thyrotropin-Releasing Hormone)                     |
|                              [ANTERIOR PITUITARY]                                                 |
|                                        |                                                          |
|                                        v (TSH: Thyroid-Stimulating Hormone)                       |
|                                 [THYROID GLAND]                                                   |
|                                        |                                                          |
|                         +--------------+--------------+                                           |
|                         |                             |                                           |
|                         v                             v                                           |
|                   [THYROXINE (T4)]          [TRIIODOTHYRONINE (T3)]                               |
|                    (~80-90% output)           (~10-20% direct output)                             |
|                         |                             |                                           |
|                         +--------------+--------------+                                           |
|                                        |                                                          |
|                                        v                                                          |
|                     [PERIPHERAL 5'-DEIODINATION IN TISSUES]                                       |
|                     (T4 converted to biologically active T3)                                      |
|                                        |                                                          |
|                                        +------------------------------------+                     |
|                                                                             |                     |
|                                  [NEGATIVE FEEDBACK]                        |                     |
|   - Elevated Free T4/T3 suppresses TRH and TSH secretion -------------------+                     |
|   - Decreased Free T4/T3 stimulates TRH and TSH secretion                                         |
+---------------------------------------------------------------------------------------------------+

Diagnostic Serological Patterns in Thyroid Pathology

Diagnostic PatternSerum TSHSerum Free T4Serum Free T3Clinical Etiologies & Diagnostic Pearls
Primary HypothyroidismElevated ($\uparrow$)Decreased ($\downarrow$)Normal or LowHashimoto's thyroiditis, post-ablative (131-I), surgical thyroidectomy, end-stage severe iodine deficiency.
Subclinical HypothyroidismElevated ($\uparrow$)Normal ($\leftrightarrow$)NormalEarly Hashimoto's; recover phase of thyroiditis; check anti-TPO antibodies; treat if TSH $>10\text{ mIU/L}$ or symptomatic.
Secondary / Central HypothyroidismLow or Inappropriately Normal ($\downarrow / \leftrightarrow$)Decreased ($\downarrow$)LowPituitary macroadenoma, Sheehan syndrome, craniopharyngioma, brain radiation. TSH is uninformative for monitoring!
Primary HyperthyroidismSuppressed ($<0.01$)Elevated ($\uparrow$)Elevated ($\uparrow$)Graves' disease, Toxic Multinodular Goiter, Toxic Solitary Adenoma, early phase thyroiditis.
T3 ToxicosisSuppressed ($<0.01$)Normal ($\leftrightarrow$)Elevated ($\uparrow$)Early Graves' disease, autonomous toxic nodule. Always order Free T3 if TSH is suppressed but Free T4 is normal!
Subclinical HyperthyroidismSuppressed ($<0.1$)Normal ($\leftrightarrow$)Normal ($\leftrightarrow$)Exogenous over-replacement, mild multinodular goiter. High risk for AFib and osteoporosis in older adults.
Euthyroid Sick SyndromeNormal / Low / HighNormal / LowDecreased ($\downarrow$)Non-thyroidal critical illness (ICU, severe sepsis). Deiodinase inhibition; elevated Reverse T3 (rT3). Do NOT treat with levothyroxine!

2. Hypothyroidism: Pathophysiology, Clinical Manifestations & Levothyroxine Mastery

A. Etiologies & Pathophysiology

  1. Hashimoto's Thyroiditis (Chronic Autoimmune Thyroiditis): The most common cause of hypothyroidism in iodine-replete areas. Characterized by cell-mediated lymphocytic infiltration (CD4+ and CD8+ T-cells) and autoantibody-mediated follicular destruction. Serological markers include anti-Thyroid Peroxidase (anti-TPO) antibodies (positive in >95%) and anti-Thyroglobulin (anti-Tg) antibodies (positive in 60–80%).
  2. Iatrogenic / Post-Procedural: Following radioactive iodine (131-I) ablation for Graves' disease, total/subtotal thyroidectomy, or external beam neck radiation.
  3. Drug-Induced Hypothyroidism:
    • Amiodarone: Contains 37% iodine by molecular weight. Induces hypothyroidism in ~15–20% of patients via the Wolff-Chaikoff effect (high iodine load transiently inhibits thyroid organification) or direct cytotoxic destructive thyroiditis.
    • Lithium: Inhibits thyroid hormone synthesis and peripheral release (goitrogenic; monitor TSH every 6–12 months).
    • Immune Checkpoint Inhibitors (PD-1/PD-L1/CTLA-4 Inhibitors): Pembrolizumab, nivolumab, ipilimumab trigger autoimmune hypophysitis or destructive thyroiditis.

B. Multi-System Clinical Presentation

  • Constitutional & Metabolic: Extreme fatigue, cold intolerance, unexplained modest weight gain (primarily myxedematous fluid retention, rarely >5–10 lbs), hypothermia, slow speech.
  • Cardiovascular: Sinus bradycardia, narrow pulse pressure, diastolic hypertension (increased systemic vascular resistance), pericardial effusion, elevated LDL-cholesterol (downregulation of hepatic LDL receptors).
  • Neuromuscular & Neuropsychiatric: "Brain fog", depression, memory loss, proximal muscle weakness, elevated creatine kinase (CK), carpal tunnel syndrome (median nerve compression by mucopolysaccharide deposits), delayed relaxation phase of deep tendon reflexes (Woltman's sign / hung-up reflexes).
  • Dermatologic & ENT: Dry, scaly skin (xerosis), coarse, brittle, thinning hair, loss of the lateral third of the eyebrows (madarosis / Queen Anne's sign), non-pitting periorbital and pretibial edema (myxedema due to hyaluronic acid deposition in the dermis), hoarseness/deepened voice.
  • Gastrointestinal & Reproductive: Severe constipation, paralytic ileus, menorrhagia (early) or amenorrhea (late), galactorrhea (elevated TRH stimulates anterior pituitary prolactin release).
+---------------------------------------------------------------------------------------------------+
|                         LEVOTHYROXINE (L-THYROXINE, T4) DOSING PROTOCOL                           |
|                                                                                                   |
|   [HEALTHY YOUNG ADULT (<50 YRS, NO CAD)]                                                         |
|   - Full Replacement Dose: 1.6 mcg/kg/day (Calculate using Ideal Body Weight, IBW)                |
|   - Example: 70 kg patient -> ~112 mcg daily (prescribe 100-112 mcg/day)                          |
|                                                                                                   |
|   [OLDER ADULT (>=50-65 YRS) OR PATIENT WITH CORONARY ARTERY DISEASE / MULTIMORBIDITY]            |
|   - "START LOW AND GO SLOW": Starting Dose: 12.5 to 25 mcg/day (or 25 to 50 mcg/day)            |
|   - Rationale: Rapid restoration of euthyroidism increases myocardial oxygen demand, precipitating|
|     acute angina, myocardial infarction, or fatal ventricular arrhythmias.                        |
|   - Titration: Increase by 12.5 - 25 mcg increments every 6 to 8 weeks based on serum TSH.        |
|                                                                                                   |
|   [PREGNANCY]                                                                                     |
|   - Increase dose by 25 - 30% (e.g., take 2 extra doses per week) immediately upon confirmation   |
|     of pregnancy; TSH goal < 2.5 mIU/L in 1st trimester.                                          |
+---------------------------------------------------------------------------------------------------+

Levothyroxine Administration & Drug-Nutrient Absorption Interferences

Levothyroxine absorption occurs primarily in the jejunum and ileum, requiring an acidic gastric microenvironment. The AGPCNP must educate every patient on strict administration rules:

  • Timing: Take immediately upon waking on an empty stomach with a full 8-ounce glass of plain water, at least 30 to 60 minutes before breakfast, or at bedtime at least 3 to 4 hours after the last meal.
  • Medication Separation (The 4-Hour Rule): The following substances bind levothyroxine in the gut lumen, drastically reducing bioavailability. Separate by a minimum of 4 hours:
    • Calcium carbonate and calcium citrate supplements.
    • Ferrous sulfate / iron supplements.
    • Aluminum-containing antacids, sucralfate, and magnesium hydroxide.
    • Bile acid sequestrants (cholestyramine, colestipol, colesevelam).
    • Proton Pump Inhibitors (PPIs) and H2-receptor antagonists (impair acid-dependent dissolution).
    • Multivitamins containing minerals, soy protein products, and high-fiber supplements.
  • Monitoring: Recheck serum TSH 6 to 8 weeks after initiating therapy or after any dose modification. Once euthyroid, monitor TSH annually or whenever symptoms change.

C. Myxedema Coma (Decompensated Hypothyroidism)

  • Pathophysiology & Triggers: Life-threatening medical emergency (mortality 30–50%) resulting from longstanding, severe untreated hypothyroidism complicated by an acute physiological stressor (severe infection, sepsis, myocardial infarction, cold exposure, trauma, or central nervous system depressants).
  • Hallmark Triad: Hypothermia (temperature frequently $<35^\circ\text{C} [95^\circ\text{F}]$), Altered Mental Status (lethargy, obtundation, myxedema madness, coma), and Cardiorespiratory Depression (bradycardia, severe hypotension, hypoventilation with hypercapnia).
  • Diagnostic Lab Clues: Hyponatremia (impaired free water clearance / SIADH-like state), hypoglycemia, elevated creatinine kinase, low Free T4/Free T3, highly elevated TSH.
  • Emergency Treatment Protocol:
    1. IV Glucocorticoids (MANDATORY FIRST STEP): Administer IV Hydrocortisone 100 mg q8h prior to or concurrently with thyroid hormone replacement. (Treating with thyroid hormone alone accelerates cortisol clearance and precipitates fatal adrenal crisis in patients with co-existing autoimmune adrenal insufficiency or central hypopituitarism).
    2. IV Thyroid Hormone Replacement: IV Levothyroxine loading dose (200–400 mcg IV bolus, then 50–100 mcg IV daily) $\pm$ IV Liothyronine (T3: 5–20 mcg loading dose).
    3. Supportive Care: Passive external rewarming (avoid active warming blankets which cause peripheral vasodilation and vascular collapse), mechanical ventilation for hypercapnic failure, IV 5% Dextrose in normal saline for hypoglycemia/hyponatremia, and broad-spectrum IV antibiotics for occult sepsis.

3. Hyperthyroidism & Thyrotoxicosis: Etiology, RAIU Differentiation & Management

+---------------------------------------------------------------------------------------------------+
|                         24-HOUR RADIOACTIVE IODINE UPTAKE (RAIU) SCAN                             |
|                                                                                                   |
|                                   [SUPPRESSED TSH + HIGH FREE T4/T3]                              |
|                                                   |                                               |
|                                                   v                                               |
|                                      [PERFORM 24-HR RAIU & SCAN]                                  |
|                                                   |                                               |
|         +-----------------------------------------+-----------------------------------------+     |
|         |                                                                                   |     |
|         v                                                                                   v     |
|   [HIGH / NORMAL UPTAKE (>15-30%)]                                            [LOW / SUPPRESSED (<5%)]    |
|   (True De Novo Hyperthyroidism)                                              (Thyroiditis / Exogenous)   |
|         |                                                                                   |     |
|   +-----+-----------------------+-----------------------+                                   |     |
|   |                             |                       |                                   |     |
|   v                             v                       v                                   v     |
|  [DIFFUSE HOMOGENEOUS]   [MULTIPLE PATCHY HOT]   [SINGLE HOT FOCUS]                  [THYROIDITIS / EXOGENOUS]|
|  = GRAVES' DISEASE       = TOXIC MULTINODULAR    = TOXIC ADENOMA                     - Subacute (De Quervain)|
|  - Positive TSI / TRAb     GOITER (PLUMMER)      - Suppressed baseline               - Postpartum / Silent |
|  - Exophthalmos, bruit   - Elderly, patchy RAIU    parenchyma                        - Factitious (Low Tg) |
|  - Pretibial myxedema    - Autonomous nodules                                        - Iodine-induced      |
+---------------------------------------------------------------------------------------------------+

A. Graves' Disease (Autoimmune Hyperthyroidism)

  • Pathophysiology: Autoimmune disorder caused by circulating Thyroid-Stimulating Immunoglobulins (TSI) or TSH-receptor antibodies (TRAb) that bind to and chronically activate the follicular TSH receptor, driving autonomous thyroid hormone synthesis, hypertrophy, and hyperplasia.
  • Extrathyroidal Pathognomonic Manifestations:
    • Graves' Orbitopathy / Ophthalmopathy (25–50%): Proptosis, periorbital edema, diplopia, chemosis, lid retraction, and optic nerve compression due to T-cell mediated retro-orbital fibroblast activation and glycosaminoglycan accumulation.
    • Pretibial Myxedema (Thyroid Dermopathy): Non-pitting, violaceous, indurated, "orange-peel" (peau d'orange) plaques over the anterior shins.
    • Thyroid Acropachy: Digital clubbing and subperiosteal bone formation.
    • Thyroid Bruit / Thrill: Audible continuous systolic-diastolic vascular murmur over the thyroid lobes reflecting dramatic hypervascularity.

B. Toxic Multinodular Goiter (TMNG / Plummer Disease) & Toxic Adenoma

  • Autonomous somatic mutations in the TSH receptor gene occurring in longstanding non-toxic multinodular goiters. Most common in older adults (>60 years).
  • Manifests without orbitopathy or pretibial myxedema. Patients frequently present with "Apathetic Hyperthyroidism" characterized by depression, lethargy, anorexia, proximal muscle wasting, and new-onset Atrial Fibrillation refractory to standard rate control.

C. Pharmacotherapy & Definitive Management of Hyperthyroidism

+---------------------------------------------------------------------------------------------------+
|                         HYPERTHYROIDISM PHARMACOLOGICAL MANAGEMENT                                |
|                                                                                                   |
|   1. SYMPTOM CONTROL (BETA-BLOCKERS)                                                              |
|   - Propranolol (20-80 mg PO q6-8h) OR Atenolol (25-100 mg daily).                                |
|   - Action: Rapidly blunts adrenergic hyperactivity (tachycardia, tremor, palpitations, anxiety); |
|     High-dose propranolol also inhibits peripheral 5'-deiodinase (blocks T4 to T3 conversion).    |
|                                                                                                   |
|   2. THIONAMIDES (ANTITHYROID DRUGS)                                                              |
|   - METHIMAZOLE (MMI, 10-40 mg daily): Preferred first-line agent for almost all non-pregnant    |
|     patients due to once-daily dosing, rapid euthyroid restoration, and lower hepatotoxicity.     |
|   - PROPYLTHIOURACIL (PTU, 100-200 mg TID): Preferred ONLY in:                                    |
|     * First trimester of pregnancy (MMI is teratogenic: aplasia cutis, choanal atresia).        |
|     * Thyroid Storm (blocks peripheral T4 -> T3 conversion in addition to synthesis).             |
|     * Patients with adverse reactions to MMI where surgery/RAI is not feasible.                   |
|                                                                                                   |
|   3. DEFINITIVE THERAPY                                                                           |
|   - Radioactive Iodine Ablation (131-I): Treatment of choice for Graves' and TMNG in US; causes   |
|     permanent hypothyroidism within 3-6 months. Contraindicated in pregnancy and severe orbitopathy.|
|   - Total Thyroidectomy: Indicated for large obstructive goiters, suspected malignancy, or severe |
|     Graves' ophthalmopathy. Pre-op prep: Euthyroid with MMI + Lugol's iodine to reduce vascularity.|
+---------------------------------------------------------------------------------------------------+

[!CAUTION] Life-Threatening Thionamide Complications:

  1. Agranulocytosis (Absolute Neutrophil Count $<500/\mu\text{L}$): Occurs in 0.2–0.5% of patients on MMI or PTU, typically within the first 90 days. Presenting symptoms: acute high fever and severe sore throat / pharyngitis. The AGPCNP must educate the patient to immediately stop the medication and present for an emergent Complete Blood Count (CBC) with differential. Never treat empirically with oral antibiotics without a CBC.
  2. Hepatotoxicity: PTU carries an FDA Black Box Warning for Fulminant Hepatic Failure (hepatocellular necrosis). MMI carries a risk of cholestatic jaundice (elevated alkaline phosphatase and bilirubin). Obtain baseline liver function tests before starting thionamides.

D. Thyroid Storm (Accelerated Thyrotoxic Crisis)

  • Clinical Presentation: Acute life-threatening crisis (mortality 10–30%) triggered by infection, surgery, trauma, or radioiodine therapy in an untreated thyrotoxic patient. Quantified using the Burch-Wartofsky Point Scale (evaluates thermoregulatory, CNS, cardiovascular, and gastrointestinal/hepatic dysfunction).
  • Hallmark Features: Severe hyperpyrexia ($39\text{--}41^\circ\text{C} [102\text{--}106^\circ\text{F}]$), marked tachycardia ($>140\text{ bpm}$), atrial fibrillation, congestive heart failure, extreme agitation, delirium, psychosis, nausea, vomiting, diarrhea, jaundice, and shock.
  • The Four-Step Sequential Medical Protocol:
    1. Step 1: Beta-Blockade: IV Propranolol (1–2 mg IV q15min or 60–80 mg PO q4h) to control sympathetic overdrive and inhibit peripheral deiodination.
    2. Step 2: Antithyroid Synthesis Blockade: PTU 500–1,000 mg loading dose PO/NG, then 200–250 mg q4h (preferred over MMI due to dual action).
    3. Step 3: Thyroid Hormone Release Blockade (Inorganic Iodine): Saturated Solution of Potassium Iodide (SSKI 5 drops PO q6h) or Lugol's solution (10 drops PO q8h). CRITICAL TIMING RULE: Inorganic iodine must be administered at least 1 hour AFTER the thionamide dose. Giving iodine before thionamide provides substrate for new hormone synthesis (Wolff-Chaikoff vs. Jod-Basedow catastrophe).
    4. Step 4: Corticosteroid Therapy: IV Hydrocortisone (100 mg IV q8h) or Dexamethasone (2 mg IV q6h) to treat relative adrenal insufficiency and further block peripheral T4 to T3 conversion.

4. The Thyroiditis Spectrum: Painful vs. Painless Subtypes

+---------------------------------------------------------------------------------------------------+
|                             THE THYROIDITIS SPECTRUM DECISION MATRIX                              |
|                                                                                                   |
|   SUBTYPE                ETIOLOGY & MECHANISM      PAIN STATUS    LAB & RAIU PROFILE   TREATMENT   |
|   ---------------------------------------------------------------------------------------------   |
|   Subacute Granulomatous Post-viral (Coxsackie,    EXQUISITELY    ESR/CRP markedly     NSAIDs or  |
|   (De Quervain / Giant)  mumps, adenovirus).       PAINFUL /      elevated (>50-100);  Prednisone |
|                          Granulomatous rupture.    TENDER GLAND   RAIU < 5%; Triphasic | (No MMI) |
|   Subacute Lymphocytic   Autoimmune variant.       PAINLESS       Anti-TPO positive    Beta-blocker|
|   (Silent Thyroiditis)   Lymphocytic infiltrate.   (Non-tender)   in 50%; RAIU < 5%;   for hyper-  |
|                                                                   Self-limiting        thyroid phase|
|   Postpartum             Autoimmune within 12 mo   PAINLESS       Anti-TPO positive    Beta-blocker|
|   Thyroiditis            of delivery; rebound.     (Non-tender)   in 80%; RAIU < 5%;   (Avoid MMI/|
|                                                                   Triphasic course     PTU / RAI) |
|   Acute Suppurative      Bacterial infection       SEVERELY       Marked leukocytosis; IV Ceftriaxone|
|   Thyroiditis            (Staph, Strep, piriform). PAINFUL + ERY- Normal thyroid fxn;  + Vanco +   |
|                                                    THEMA/WARMTH   Abscess on ultrasound| Drainage  |
|   Riedel's Thyroiditis   IgG4 systemic fibrosing   PAINLESS       Normal/hypothyroid;  Surgical   |
|                          disorder; woody fibrosis. "STONE-HARD"   Cold scan; extensive decompression|
|                                                    FIXED GLAND    local invasion       + Tamoxifen|
+---------------------------------------------------------------------------------------------------+

The Triphasic Clinical Trajectory of Destructive Thyroiditis:

In subacute, silent, and postpartum thyroiditis, follicular cell destruction triggers a predictable 3-phase course:

  1. Hyperthyroid Phase (Weeks 1–6): Pre-formed thyroid hormone leaks into the circulation $\rightarrow$ low TSH, high Free T4/T3, RAIU is suppressed (<5%). Treat solely with beta-blockers (propranolol) for symptoms. Thionamides (MMI/PTU) and radioiodine are completely ineffective and contraindicated because there is no new hormone synthesis!
  2. Hypothyroid Phase (Weeks 6–16): Thyroid hormone stores are depleted while follicular cells recover $\rightarrow$ elevated TSH, low Free T4. If symptomatic, initiate temporary, low-dose levothyroxine.
  3. Recovery / Euthyroid Phase (Months 4–12): 90–95% of patients recover full baseline thyroid function; ~5% develop permanent hypothyroidism requiring lifelong levothyroxine.

5. Thyroid Nodules & Thyroid Cancer: Diagnostic Workup & TI-RADS Stratification

Thyroid nodules are identified in up to 50–60% of healthy adult women on high-resolution neck ultrasonography. The primary clinical objective is excluding the 5–10% that harbor thyroid carcinoma.

+---------------------------------------------------------------------------------------------------+
|                         EVALUATION ALGORITHM FOR THE PALPABLE THYROID NODULE                      |
|                                                                                                   |
|                           [PALPABLE NODULE OR INCIDENTAL FINDING ON CT/US]                        |
|                                                   |                                               |
|                                                   v                                               |
|                                     [ORDER SERUM TSH LEVEL]                                       |
|                                                   |                                               |
|                       +---------------------------+---------------------------+                   |
|                       |                                                       |                   |
|                       v                                                       v                   |
|             [SUPPRESSED TSH (<0.4)]                                 [NORMAL OR ELEVATED TSH]      |
|                       |                                                       |                   |
|                       v                                                       v                   |
|         [RADIONUCLIDE SCAN (I-123)]                                 [HIGH-RESOLUTION NECK US]     |
|                       |                                                       |                   |
|         +-------------+-------------+                                         v                   |
|         |                           |                               [STRATIFY VIA ACR TI-RADS]    |
|         v                           v                                         |                   |
|    ["HOT" (FUNCTIONING)]      ["COLD" (NON-FUNCTIONING)]                      v                   |
|    - Autonomous adenoma       - Malignancy risk ~10-15%             [FINE NEEDLE ASPIRATION (FNA)]|
|    - Malignancy < 1%          - Proceed to NECK US &                 Based on TI-RADS score and    |
|    - Treat hyperthyroidism      FNA based on TI-RADS criteria        size thresholds (>=1.0-1.5 cm)|
+---------------------------------------------------------------------------------------------------+

High-Risk Sonographic Features (ACR TI-RADS):

  • Solid composition (vs. cystic or spongiform).
  • Hypoechogenicity (darker than adjacent strap muscles).
  • Taller-than-wide morphology (anteroposterior diameter > transverse diameter on transverse view).
  • Irregular, lobulated, or infiltrative margins (or extrathyroidal extension).
  • Punctate echogenic foci / Microcalcifications (represent psammoma bodies).

Thyroid Malignancy Classification Matrix

Carcinoma SubtypePrevalenceHistopathology & Genetic DriversClinical Behavior & Metastatic RoutePrognosis & Management
Papillary Thyroid Carcinoma (PTC)80 - 85%• Psammoma bodies<br>• "Orphan Annie eyes" (ground-glass nuclei)<br>• Nuclear grooves<br>• BRAF V600E, RET/PTCIndolent; spreads primarily via cervical lymphatics; history of neck radiation exposure.Excellent (10-yr survival >95%)<br>Lobectomy or total thyroidectomy $\pm$ 131-I ablation $\pm$ TSH suppression.
Follicular Thyroid Carcinoma (FTC)10 - 15%• Capsular and/or vascular invasion<br>• RAS mutations, PAX8-PPARG<br>• (FNA cannot distinguish adenoma vs cancer)Spreads hematogenously to bone and lungs; common in iodine-deficient areas.Good (10-yr survival ~85%)<br>Total thyroidectomy + 131-I ablation; monitor serum Thyroglobulin (Tg) as tumor marker.
Medullary Thyroid Carcinoma (MTC)4 - 5%• Originates from parafollicular C-cells<br>• Amyloid stroma (calcitonin deposits)<br>• RET proto-oncogene (MEN 2A/2B)Calcitonin and CEA secreting; spreads to lymph nodes, liver, bone.Moderate (10-yr survival ~75%)<br>Total thyroidectomy + central neck dissection. Screen for Pheochromocytoma before surgery!
Anaplastic Thyroid Carcinoma< 2%• Highly undifferentiated pleomorphic spindle cells<br>• TP53 mutationsExtremely aggressive; rapid neck mass growth with hoarseness (RLN palsy), stridor, dysphagia.Dismal (Median survival 3-6 mo)<br>Palliative airway management, radiation, chemotherapy (rarely operable).

6. Board-Yield Summary & Clinical Pearls

+---------------------------------------------------------------------------------------------------+
|                                 ANCC AGPCNP CLINICAL EXAM PEARLS                                  |
|                                                                                                   |
|   - Start Low, Go Slow in Geriatrics / CAD: Never initiate full-dose levothyroxine in an older     |
|     adult or patient with CAD (start 12.5-25 mcg/day). Rapid titration induces fatal MI / AFib.   |
|                                                                                                   |
|   - Thionamide S.O.S.: Sore throat and fever in a patient on Methimazole or PTU = AGRANULOCYTOSIS   |
|     until proven otherwise! Stop drug immediately and draw STAT CBC with differential.            |
|                                                                                                   |
|   - Pregnancy Thionamide Rule: 1st Trimester = PTU (prevents MMI aplasia cutis); 2nd and 3rd       |
|     Trimesters = Methimazole (prevents PTU fulminant hepatic necrosis).                            |
|                                                                                                   |
|   - Thyroiditis Rule: Subacute painful thyroiditis = High ESR + Low RAIU (<5%). Do NOT prescribe  |
|     Methimazole or PTU! Treat hyperthyroid symptoms with beta-blockers and pain with NSAIDs/steroids.|
|                                                                                                   |
|   - Thyroid Nodule Workup First Step: Check Serum TSH. Low TSH -> Radionuclide scan; Normal/High   |
|     TSH -> High-resolution Neck Ultrasound -> FNA based on TI-RADS.                               |
+---------------------------------------------------------------------------------------------------+
Test Your Knowledge

A 72-year-old female with a history of hypertension, osteoporosis, and ischemic cardiomyopathy (LVEF 35%, post-anterior MI 4 years ago) presents for a Medicare Annual Wellness Visit. Routine laboratory testing reveals: serum TSH 14.8 mIU/L (normal: 0.4–4.5 mIU/L) and Free T4 0.5 ng/dL (normal: 0.8–1.8 ng/dL). She reports mild constipation and dry skin, which she attributed to aging. Vital signs: BP 134/82 mmHg, HR 58 bpm, weight 68 kg (150 lbs). Which of the following represents the most appropriate initial pharmacological management by the AGPCNP?

A
B
C
D
Test Your Knowledge

A 34-year-old female presents to the primary care clinic complaining of anterior neck pain, palpitations, nervousness, and a 6-pound weight loss over the past 2 weeks. She reports recovering from a severe upper respiratory viral infection 3 weeks ago. On physical examination, her thyroid gland is exquisitely tender to palpation and mildly enlarged bilaterally, without discrete nodules. Vital signs: BP 138/84 mmHg, HR 106 bpm, Temp 37.8°C (100.0°F). Laboratory testing reveals: TSH < 0.01 mIU/L, Free T4 2.8 ng/dL (elevated), Erythrocyte Sedimentation Rate (ESR) 88 mm/hr (normal: <20 mm/hr), and C-Reactive Protein (CRP) 42 mg/L. A 24-hour Radioactive Iodine Uptake (RAIU) scan demonstrates a diffuse uptake of 1.2% (normal: 15–30%). What is the most appropriate management plan?

A
B
C
D
Test Your Knowledge

A 48-year-old female presents for evaluation of a newly discovered, painless anterior neck mass. Physical examination confirms a firm, non-tender, 1.8-cm solitary nodule in the right thyroid lobe. She has no dysphagia, hoarseness, or history of head/neck radiation. Her serum TSH is 1.8 mIU/L (normal: 0.4–4.5 mIU/L). High-resolution neck ultrasonography reveals a solid, hypoechoic 1.8-cm nodule with irregular, infiltrative margins, taller-than-wide dimensions, and punctate microcalcifications. Which of the following is the most appropriate next step in clinical management?

A
B
C
D
Up Next

7.3 Adrenal & Pituitary Disorders: Adrenal Insufficiency, Cushing's, Hyperaldosteronism & Hypopituitarism

Continue learning